Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03181828 · ClinicalTrials.gov registry record · Phase 1
Manipulating the Gut Microbiome Study
A Phase 1 study, sponsored by Nicholas Ah Mew.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT03181828: Clinical Trial Phase 1 study, sponsored by Nicholas Ah Mew.
NCT03181828 is a Phase 1 study that was terminated before completion, run by Nicholas Ah Mew. The registered enrollment target is 4 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03181828, a Phase 1 study, was terminated before completion, sponsored by Nicholas Ah Mew.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
The objective is to determine if acetohydroxamic acid (AHA) can prevent hydrolysis of urea by inhibiting the bacterial urease of gut flora of both healthy control adults as well as adults with urea cycle disorders
Primary Outcome
Difference in the % enrichment of Carbon-13 in blood CO2 as compared to baseline measurement, at sequential time points, after a single bolus of intravenous \[13C\]-Urea,
Interventions
- OTHER No treatment
- DRUG Acetohydroxamic Acid Oral Tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2017-03-24 |
| Est. Completion | 2018-06-05 |
| Phase | Phase 1 |
Why NCT03181828 stopped before completion
NCT03181828 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 2 interventions - of which No treatment is the first listed.
NCT03181828 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03181828 about?
NCT03181828 is a clinical study titled "Manipulating the Gut Microbiome Study". The objective is to determine if acetohydroxamic acid (AHA) can prevent hydrolysis of urea by inhibiting the bacterial urease of gut flora of both healthy control adults as well as adults with urea cycle disorders
What is the current status of trial NCT03181828?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2017-03-24. Estimated completion is 2018-06-05.
What interventions are being tested in trial NCT03181828?
The interventions under investigation include: No treatment (OTHER), Acetohydroxamic Acid Oral Tablet (DRUG).
Who is sponsoring clinical trial NCT03181828?
This trial is sponsored by Nicholas Ah Mew, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03181828's enrollment target sits among peer trials
4 1995th of 2000 higher than 2 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI